I think if you look at the Board, you will see that it is heavily loaded with biotech expertise. More recently, it has been loading up on retail expertise (I would argue that Advangen sells consumer health goods, not beauty products, but admittedly the consumer may not recognise the difference). Von Rico's comments may accurately explain the company's progress to date, but I don't think it can be argued that it lacks expertise in both areas now - and elite expertise, at that.
CDY Price at posting:
38.0¢ Sentiment: Buy Disclosure: Held